| (Values in U.S. Thousands) | Dec, 2016 | Sep, 2016 | Jun, 2016 | Mar, 2016 | Dec, 2015 |
| Sales | -9,999,000 | -9,999,000 | -9,999,000 | -9,999,000 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -9,999,000 | -2,120 | -9,999,000 | -15,270 |
| Net Income Growth | unch | -471,551.17% | +99.98% | -65,381.34% | -161.92% |
Macrocure Ltd. Or Sh (MCUR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Macrocure Ltd. is a clinical-stage biopharmaceutical company. It is focused on developing a therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The company's lead cell-based biological product includes CureXcell, which is in two pivotal Phase III clinical trials. It is an injectable suspension of living human white blood cells, including macrophages, neutrophils and lymphocytes, for the treatment of hard-to-heal diabetic foot ulcers and hard-to-heal venous leg ulcers. Macrocure Ltd. is based in Petach Tikva, Israel.
Fiscal Year End Date: 12/31